Assessment of human papillomavirus E6-E7 oncogene expression as cervical disease biomarkerReportar como inadecuado




Assessment of human papillomavirus E6-E7 oncogene expression as cervical disease biomarker - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 16:852

Infection, immunity and cancer vaccines

Abstract

BackgroundThe aims of this study were to detect HPV E6-E7 mRNA expression in women with high-risk genotypes HPV-16 -18 -31 -33 and -45 analysing its relationship with tissue pathology and 2 2-year follow-up of E6-E7 mRNA tested group.

MethodsOur samples were genotyped and classified by pathologists according to Bethesda system. After RNA extraction, E6-E7 oncogene mRNA detection was performed by NucliSens® EasyQ® HPV v1 Test bioMérieux.

ResultsThe results of the present study showed that E6-E7 mRNA positivity rate was 68.29 % in women tested once and 69.56 % in women tested twice. According to tissue pathology, all samples with high-grade lesions were positive for mRNA. Among women with low-grade lesions varied over the years from 89.28 to 84 % in women tested once and from 77.77 to 70 % in tested twice. Among women without lesion, positivity rate maintained in women tested once from 50 to 41.38 % and decreased in tested twice, from 63.63 to 44.44 %. Regarding lesion evolution, mRNA positivity was higher in women with lesion progression 53.13 % and in women with positive results in two tested samples 83.33 %.

ConclusionHPV E6-E7 mRNA detection may be an effective screening test and biomarker for cervical cancer in women infected with these five genotypes. Nonetheless, further studies are needed to standardize as routine triage test.

KeywordsHigh-risk HPV genotypes E6-E7 mRNA detection Oncogenes Biomarker Prognosis marker  Download fulltext PDF



Autor: Nerea Fontecha - Miren Basaras - Silvia Hernáez - Daniel Andía - Ramón Cisterna

Fuente: https://link.springer.com/







Documentos relacionados